Researchers have discovered six candidate biomarkers for Lyme disease. A newly developed test can help identify the disease which, until now, has been notoriously difficult to detect.
Researchers have identified specific anti-bodies that can have a neutralizing effect on the virus responsible for tick-borne encephalitis. Preliminary response in using the anti-bodies in mice has proven affected in preventing TBE. It is hoped a vaccine candidate for TBE can be developed for humans.
Engineers have developed a new device that can significantly reduce the cost of testing for diseases such as HIV and Lyme disease. The Lab on a Chip technology may also be used to promote central nervous system research.
Ethnobotanical plant extracts, including Ghanaian quinine and Japanese knotweed, show strong activity against B.burgdorferi, outperforming current antibiotics for the treatment of Lyme disease.
People with no prior mental health diagnosis who contract Lyme disease have a 42% higher risk of developing an affective disorder, such as depression, and a 75% higher rate of death by suicide than those without the disease.
A new vaccine for Lyme disease, a neurological and physically debilitating tick borne disease, has proved promising and well tolerated by patients, according to researchers. The Lyme vaccine is shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease.
Important clues about the causes of MS could be found in gray matter, a new study suggests.
A new neuroimaging study reveals 12 people with documented post-treatment Lyme disease syndrome have an elevation of a chemical marker associated with neuroinflammation. The findings could help develop new treatments for the pain, fatigue and brain fog associated with PTLDS.
Researchers have developed new techniques which are able to diagnose Lyme disease bacteria weeks sooner than currently available tests.
Mouse study reveals the antibiotic azlocillin completely kills off the Borrelia burgdorferi bacteria at the onset of Lyme disease. Findings also suggest the drug could be effective for treating patients infected with drug-tolerant bacteria that may cause lingering symptoms.